Xintela AB (Sweden) Profile

3.13
SEK 0.01  0.32%
24%
81%

Xintela AB Summary

Xintela AB (XINT) is traded on Stockholm Stock Exchange in Sweden. It is located in Scheelev?gen 2 and employs 12 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 95.05 M. Xintela AB operates under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 30.37 M outstanding shares. The company has accumulated about 11.92 M in cash with (19.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Check Xintela AB Probability Of Bankruptcy

Xintela AB Risk Profiles

Key Fundamentals

Xintela AB Against Markets

Current Ratings

Xintela AB 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 75% 
Equity ratings for Xintela AB are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Xintela AB , a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company was founded in 2009 and is based in Lund, Sweden. Xintela AB operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange exchange. more
NameXintela AB
CEOEvy LundgrenAkerlundAll Leadership
Macroaxis Advice
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentSweden Stock Stocks Directory
Business AddressScheelev?gen 2
ExchangeStockholm Stock Exchange
ISINSE0007756903
SectorHealthcare
IndustryPharmaceuticals And Biosciences
BenchmarkDOW
Websitewww.xintela.se
CurrencySEK - Swedish Kronor

Directors

Xintela AB Corporate Directors
Sven Kili Director
Liselotte Theorell Director Product Development and Quality Management
Keld Soendergaard Director

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Directors

Xintela AB Corporate Directors
Sven Kili Director
Liselotte Theorell Director Product Development and Quality Management
Keld Soendergaard Director